Search - tctmd.com

Displaying 841 - 860 of 1353

Sort: Relevancy | Date

Presentation TVT 2019

Which Patients Are Best Candidates for Clinical Trials With… Transcatheter Leaflet/Chordal Suspension (Anatomic and Clinical Factors)

Presenter: Steven Bolling

June 14, 2019

Presentation TVT 2019

COAPT: Perspectives on Clinical Trial Data and Anticipated US Patient Selection Criteria for FMR

Presenter: Gregg Stone

June 14, 2019

Presentation TVT 2019

MITRA-FR: Perspectives on Clinical Trial Data and Current EU Patient Selection Criteria for FMR

Presenter: Bernard Prendergast

June 14, 2019

News Conference News TVT 2019

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

Shelley Wood

June 13, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Presentation TVT 2019

Technology Description, Clinical Data and Plans for the US Pivotal Trial

Presenter: Martin Leon

June 13, 2019

Presentation TVT 2019

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Presenter: Martin Leon

June 13, 2019

Presentation TVT 2019

The LOTUS Edge TAVR System: Clinical Trial Updates

Presenter: Chris Meduri

June 13, 2019

Presentation TVT 2019

The Next TAVR vs. SAVR Randomized Trial Should Be in Patients With Bicuspid Aortic Valves

Presenter: Raj Makkar

June 13, 2019

Presentation TVT 2019

Highlights From the CoreValve Low-Risk Trial

Presenter: Jeffrey Popma

June 13, 2019

Presentation TVT 2019

Highlights From the PARTNER 3 Low-Risk Trial

Presenter: Michael Mack

June 13, 2019

Presentation TVT 2019

Cerebral Embolic Protection for TAVR With TriGuard 3: Updates From the REFLECT Clinical Trial

Presenter: Tamim Nazif

June 13, 2019

Presentation TVT 2019

Do We Need a Randomized Trial of VIV vs. Redo SAVR for Failed Bioprosthetic Surgical Valves? The REPEAT Trial

Presenter: Vinayak Bapat

June 13, 2019

Presentation TVT 2019

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A 2-Year Analysis From the SURTAVI Trial

Presenter: Mark Tuttle

June 13, 2019

Presentation TVT 2019

Proportionate and Disproportionate FMR: A New Conceptual Framework to Explain Differences in Clinical Trial Outcomes

Presenter: Paul Grayburn

June 13, 2019

Presentation TVT 2019

A Synthesis of COAPT, MitraFR, and Other FMR Trials: Clinical Implications

Presenter: Gregg Stone

June 13, 2019

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

Todd Neale

June 12, 2019

News Daily News

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Yael L. Maxwell

June 11, 2019

News Daily News

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

Michael O'Riordan

June 11, 2019

News Conference News SCAI 2019

ProGlide Comes Out Ahead of Prostar in Vascular Closure After Transfemoral TAVR: BRAVO 3

Yael L. Maxwell

June 05, 2019

Advertisement

Which Patients Are Best Candidates for Clinical Trials With… Transcatheter Leaflet/Chordal Suspension (Anatomic and Clinical Factors)

COAPT: Perspectives on Clinical Trial Data and Anticipated US Patient Selection Criteria for FMR

MITRA-FR: Perspectives on Clinical Trial Data and Current EU Patient Selection Criteria for FMR

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Technology Description, Clinical Data and Plans for the US Pivotal Trial

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

The LOTUS Edge TAVR System: Clinical Trial Updates

The Next TAVR vs. SAVR Randomized Trial Should Be in Patients With Bicuspid Aortic Valves

Highlights From the CoreValve Low-Risk Trial

Highlights From the PARTNER 3 Low-Risk Trial

Cerebral Embolic Protection for TAVR With TriGuard 3: Updates From the REFLECT Clinical Trial

Do We Need a Randomized Trial of VIV vs. Redo SAVR for Failed Bioprosthetic Surgical Valves? The REPEAT Trial

Functional Status After Transcatheter and Surgical Aortic Valve Replacement: A 2-Year Analysis From the SURTAVI Trial

Proportionate and Disproportionate FMR: A New Conceptual Framework to Explain Differences in Clinical Trial Outcomes

A Synthesis of COAPT, MitraFR, and Other FMR Trials: Clinical Implications

Potential Warning Signs Seen for NOAC Use After TAVR

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

ProGlide Comes Out Ahead of Prostar in Vascular Closure After Transfemoral TAVR: BRAVO 3

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content